Treatment of Chronic Hepatitis C Virus Infection in Children. A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition.

Indolfi, G;Hierro, L.;Jahnel, J.;Debray, D.;Fischler, B;et.al.
(2018) Pediatric Gastroenterology, Hepatology & Nutrition — Vol. 66, n° 3, p. 505-515 (2018)

Files

No attached file found for this publication.

Details

Authors
  • Indolfi, GMeyer Children's Hospital of Florenze, Italy
    Author
  • Hierro, L.Hospital Infantil La Paz, Spain
    Author
  • Jahnel, J.Medical University Graz, Austria
    Author
  • Debray, D.Hôpital Necker Enfants Malades, France
    Author
  • Smets, FrançoiseUCLouvain
    Author
  • Fischler, BUniversity of Groningen, The Netherlands and Karolinska University Hospital, Sweden
    Author
Show more
Abstract
OBJECTIVES: In 2017, the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) approved the use of the fixed-dose combination of ledipasvir/sofosbuvir and of the combination of sofosbuvir and ribavirin for treatment of adolescents (12-17 years, weighing more than 35 kg) with chronic hepatitis C virus (HCV) genotype 1, 4, 5 and 6 and genotype 2 and 3 infections, respectively. Although trials with direct acting antivirals (DAAs) are ongoing for younger children, the only available treatment in US and Europe for those < 12 years is still the dual therapy of pegylated interferon (PEG IFN) and ribavirin. There is currently a lack of a systematic approach to the care of these patients. The Hepatology Committee of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) developed an evidence-based position paper for the management of chronic HCV infection in children. METHODS: A systematic literature search and meta-analysis were performed using MEDLINE and Embase from June 1, 2007 to June 1, 2017. The approach of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) was applied to evaluate outcomes. ESPGHAN Hepatology Committee members voted on each recommendation, using the nominal voting technique. RESULTS: The efficacy of the different DAAs combinations tested was higher, the relapse and the treatment discontinuation rates lower when compared to PEG IFN and ribavirin. CONCLUSIONS: This position paper addresses therapeutic management issues including goals, endpoints, indications, contra-indications and the optimal treatment regimen in children with chronic HCV infection.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Indolfi, G., Hierro, L., Jahnel, J., Debray, D., Hadzic, N., Czubowski, P., Gupte, G., Mozer-Glassberg, Y., Van der Woerd, W., Smets, F., Verkade, H., & Fischler, B. (2018). Treatment of Chronic Hepatitis C Virus Infection in Children. A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. Pediatric Gastroenterology, Hepatology & Nutrition, 66(3), 505-515. https://doi.org/10.1097/MPG.0000000000001872 (Original work published 2018)